Tags

Type your tag names separated by a space and hit enter

Drug-induced subacute cutaneous lupus erythematosus associated with abatacept.
Lupus. 2021 Apr; 30(4):661-663.L

Abstract

Numerous drugs have been linked to the induction or exacerbation of systemic cutaneous lupus erythematosus (SCLE). This report presents the third case of the biologic abatacept as an exacerbating medication for SCLE. A 73-year old woman with a remote history of subacute cutaneous lupus and rheumatoid arthritis, well controlled on hydroxychloroquine, presented with worsening annular erythematous, slightly scaly plaques on her forearms and hands. She had been started on abatacept a month prior. She was diagnosed with SCLE exacerbated by abatacept given the clinical findings, time course, and skin biopsy with interface dermatitis. Her skin eruption cleared completely several months later after discontinuing abatacept and switching to tociluzumab, while remaining on hydroxychloroquine. This case highlights the need to consider abatacept as a potential exacerbating medication for SCLE in any patient with a new photodistributed papulosquamous eruption.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Figueredo Zamora E
Division of Dermatology, Department of Medicine, University of Louisville, Louisville, USA.
Callen JP
Division of Dermatology, Department of Medicine, University of Louisville, Louisville, USA.
Schadt CR
Division of Dermatology, Department of Medicine, University of Louisville, Louisville, USA.

MeSH

AbataceptAgedAntibodies, Monoclonal, HumanizedArthritis, RheumatoidBiopsyDrug SubstitutionFemaleFollow-Up StudiesHumansImmune Checkpoint InhibitorsLupus Erythematosus, CutaneousSkinTreatment OutcomeWithholding Treatment

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

33349110

Citation

Figueredo Zamora, Eliana, et al. "Drug-induced Subacute Cutaneous Lupus Erythematosus Associated With Abatacept." Lupus, vol. 30, no. 4, 2021, pp. 661-663.
Figueredo Zamora E, Callen JP, Schadt CR. Drug-induced subacute cutaneous lupus erythematosus associated with abatacept. Lupus. 2021;30(4):661-663.
Figueredo Zamora, E., Callen, J. P., & Schadt, C. R. (2021). Drug-induced subacute cutaneous lupus erythematosus associated with abatacept. Lupus, 30(4), 661-663. https://doi.org/10.1177/0961203320981146
Figueredo Zamora E, Callen JP, Schadt CR. Drug-induced Subacute Cutaneous Lupus Erythematosus Associated With Abatacept. Lupus. 2021;30(4):661-663. PubMed PMID: 33349110.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Drug-induced subacute cutaneous lupus erythematosus associated with abatacept. AU - Figueredo Zamora,Eliana, AU - Callen,Jeffrey P, AU - Schadt,Courtney R, Y1 - 2020/12/22/ PY - 2020/12/23/pubmed PY - 2021/10/5/medline PY - 2020/12/22/entrez KW - Cutaneous lupus KW - abatacept KW - biologic KW - drug induced subacute cutaneous lupus erythematosus KW - photodistributed skin lesions KW - subacute lupus erythematosus SP - 661 EP - 663 JF - Lupus JO - Lupus VL - 30 IS - 4 N2 - Numerous drugs have been linked to the induction or exacerbation of systemic cutaneous lupus erythematosus (SCLE). This report presents the third case of the biologic abatacept as an exacerbating medication for SCLE. A 73-year old woman with a remote history of subacute cutaneous lupus and rheumatoid arthritis, well controlled on hydroxychloroquine, presented with worsening annular erythematous, slightly scaly plaques on her forearms and hands. She had been started on abatacept a month prior. She was diagnosed with SCLE exacerbated by abatacept given the clinical findings, time course, and skin biopsy with interface dermatitis. Her skin eruption cleared completely several months later after discontinuing abatacept and switching to tociluzumab, while remaining on hydroxychloroquine. This case highlights the need to consider abatacept as a potential exacerbating medication for SCLE in any patient with a new photodistributed papulosquamous eruption. SN - 1477-0962 UR - https://www.unboundmedicine.com/medline/citation/33349110/Drug_induced_subacute_cutaneous_lupus_erythematosus_associated_with_abatacept_ DB - PRIME DP - Unbound Medicine ER -